세계의 요실금 치료제 시장 - 규모, 점유율, 동향 분석 보고서 : 유형별, 약제 클래스별, 성별, 유통 채널별, 지역별, 부문 예측(2024-2030년)

Market Size & Trends

The global urinary incontinence therapeutics market size was estimated at USD 4.37 billion in 2023 and is projected to expand at a CAGR of 4.0% from 2024 to 2030 due to the increasing prevalence of urinary incontinence (UI) among aging populations and the rising awareness about available treatments. According to a May 2023 report by Dovepress, the prevalence of female UI was found to be 24.8%, with stress UI being the most common subtype at 12.7%, followed by mixed UI at 8.0%, and urgency UI at 4.1%. The study highlighted that the prevalence of UI increased progressively with age and body mass index (BMI).

This market includes a variety of medications such as anticholinergics, beta-3 adrenergic agonists, and topical estrogens. These drugs help manage symptoms by reducing bladder contractions, increasing bladder capacity, and strengthening urethral and vaginal tissues. Market players are continuously investing in research and development to introduce more effective and safer treatments, which is propelling market growth.

The aging population is majorly driving the growth of this market. As global life expectancy increases, the number of elderly individuals is rising, leading to a higher prevalence of age-related conditions, including UI. Older adults often experience bladder control issues due to weakened pelvic floor muscles, decreased bladder capacity, and other health conditions that impact urinary function. This demographic shift significantly contributes to the growing demand for therapeutic solutions to manage and alleviate these symptoms.

Globally, the number of people aged 60 and older is projected to double from 1 billion in 2020 to 2.1 billion by 2050. As the population ages, the burden of UI and other geriatric syndromes like falls and delirium is expected to grow. This increase necessitates more effective and accessible treatments, driving research and development in this sector. Consequently, healthcare providers are focusing on improving the quality of life for older adults through better management of UI. As a result, the market is expanding, with companies investing in innovative treatments to meet the needs of this growing patient population.

In addition, advancements in drug development are significantly contributing to the growth of this market. Researchers and pharmaceutical companies are focusing on developing new drugs with better efficacy, fewer side effects, and improved delivery methods. Innovations such as extended-release formulations and combination therapies are enhancing patient compliance and treatment outcomes. For instance, in April 2024, Lupin Ltd introduced Mirabegron, a generic alternative to Mybetriq, aimed at managing overactive bladder in the U.S. Additionally, the exploration of novel drug targets and mechanisms of action is leading to the introduction of more effective therapies. These advancements not only improve the quality of life for patients but also drive market expansion by offering superior treatment options.

Furthermore, there has been a notable increase in awareness and diagnosis of urinary incontinence in recent years. Health campaigns and educational programs by healthcare organizations and pharmaceutical companies have played a crucial role in reducing the stigma associated with this condition and encouraging individuals to seek medical advice. Improved diagnostic tools and methods have also made it easier for healthcare providers to identify and classify different types of urinary incontinence, leading to more personalized and effective treatment plans. This heightened awareness and better diagnostic capabilities are expanding the patient base for UI therapeutics.

Global Urinary Incontinence Therapeutics Market Report Segmentation

This report forecasts revenue growth at country levels and provides an analysis on the latest industry trends and opportunities in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global urinary incontinence therapeutics market report based on type, gender, distribution channel, drug class, and region.

• Type Outlook (Revenue, USD Billion; 2018 - 2030)
• Stress Incontinence
• Urge Incontinence
• Overflow Incontinence
• Functional Incontinence
• Other Types
• Drug Class Outlook (Revenue, USD Billion; 2018 - 2030)
• Anticholinergics
• Beta-3 Adrenoceptor Agonists
• Alpha Blockers
• Estrogen
• Desmopressin
• Tricyclic Antidepressants
• Other Drug Classes
• Gender Outlook (Revenue, USD Billion; 2018 - 2030)
• Male
• Female
• Distribution Channel Outlook (Revenue, USD Billion; 2018 - 2030)
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Regional Outlook (Revenue, USD Billion; 2018 - 2030)
• North America

U.S.

Canada

Mexico

• Europe

UK

Germany

France

Italy

Spain

Norway

Denmark

Sweden

• Asia Pacific

Japan

China

India

Australia

South Korea

Thailand

• Latin America

Brazil

Argentina

• Middle East & Africa

South Africa

Saudi Arabia

UAE

Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Segment Definitions
  • 1.2.1. Type
  • 1.2.2. Age
  • 1.2.3. Distribution Channel
  • 1.2.4. Drug Class
  • 1.2.5. Regional Scope
  • 1.2.6. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Type outlook
  • 2.2.2. Age outlook
  • 2.2.3. Distribution channel outlook
  • 2.2.4. Drug class outlook
• 2.3. Regional outlook
• 2.4. Competitive Insights

Chapter 3. Urinary Incontinence Therapeutics Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Urinary Incontinence Therapeutics Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's Five Forces
    • 3.3.1.1. Bargaining power of suppliers
    • 3.3.1.2. Bargaining power of buyers
    • 3.3.1.3. Threat of substitutes
    • 3.3.1.4. Threat of new entrants
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Economic landscape
    • 3.3.2.3. Social landscape
    • 3.3.2.4. Technological landscape
    • 3.3.2.5. Environmental landscape
    • 3.3.2.6. Legal landscape
  • 3.3.3. Pipeline Analysis

Chapter 4. Urinary Incontinence Therapeutics Market: Type Estimates & Trend Analysis

• 4.1. Urinary Incontinence Therapeutics Market Segment Dashboard
• 4.2. Urinary Incontinence Therapeutics Market: Type Movement Analysis
• 4.3. Urinary Incontinence Therapeutics Market by Type Outlook (USD Billion)
• 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 4.5. Stress Incontinence
  • 4.5.1. Stress Incontinence Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 4.6. Urge Incontinence
  • 4.6.1. Urge Incontinence Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 4.7. Overflow Incontinence
  • 4.7.1. Overflow Incontinence Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 4.8. Functional Incontinence
  • 4.8.1. Functional Incontinence Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 4.9. Others
  • 4.9.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 5. Urinary Incontinence Therapeutics Market: Drug Class Estimates & Trend Analysis

• 5.1. Urinary Incontinence Therapeutics Market Segment Dashboard
• 5.2. Urinary Incontinence Therapeutics Market: Drug Class Movement Analysis
• 5.3. Urinary Incontinence Therapeutics Market by Drug Class Outlook (USD Billion)
• 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 5.5. Anticholinergics
  • 5.5.1. Anticholinergics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 5.6. Beta-3 Adrenoceptor Agonists
  • 5.6.1. Beta-3 Adrenoceptor Agonists Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 5.7. Alpha Blockers
  • 5.7.1. Alpha Blockers Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 5.8. Estrogen
  • 5.8.1. Estrogen Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 5.9. Desmopressin
  • 5.9.1. Desmopressin Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 5.10. Tricyclic Antidepressants
  • 5.10.1. Tricyclic Antidepressants Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 5.11. Others
  • 5.11.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 6. Urinary Incontinence Therapeutics Market: Distribution Channel Estimates & Trend Analysis

• 6.1. Urinary Incontinence Therapeutics Market Segment Dashboard
• 6.2. Urinary Incontinence Therapeutics Market: Distribution Channel Movement Analysis
• 6.3. Urinary Incontinence Therapeutics Market by Distribution Channel Outlook (USD Billion)
• 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 6.5. Hospital Pharmacies
  • 6.5.1. Hospital Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 6.6. Retail Pharmacies
  • 6.6.1. Retail Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 6.7. Online Pharmacies
  • 6.7.1. Online Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 7. Urinary Incontinence Therapeutics Market: Gender Estimates & Trend Analysis

• 7.1. Urinary Incontinence Therapeutics Market Segment Dashboard
• 7.2. Urinary Incontinence Therapeutics Market: Gender Movement Analysis
• 7.3. Urinary Incontinence Therapeutics Market by Gender Outlook (USD Billion)
• 7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 7.5. Male
  • 7.5.1. Male Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 7.6. Female
  • 7.6.1. Female Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 8. Urinary Incontinence Therapeutics Market: Regional Estimates & Trend Analysis

• 8.1. Regional Dashboard
• 8.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 8.3. North America
  • 8.3.1. U.S.
    • 8.3.1.1. Key country dynamics
    • 8.3.1.2. Regulatory framework/ reimbursement structure
    • 8.3.1.3. Competitive scenario
    • 8.3.1.4. U.S. market estimates and forecasts 2018 to 2030, (USD Million)
  • 8.3.2. Canada
    • 8.3.2.1. Key country dynamics
    • 8.3.2.2. Regulatory framework/ reimbursement structure
    • 8.3.2.3. Competitive scenario
    • 8.3.2.4. Canada market estimates and forecasts 2018 to 2030, (USD Million)
  • 8.3.3. Mexico
    • 8.3.3.1. Key country dynamics
    • 8.3.3.2. Regulatory framework/ reimbursement structure
    • 8.3.3.3. Competitive scenario
    • 8.3.3.4. Mexico market estimates and forecasts 2018 to 2030, (USD Million)
• 8.4. Europe
  • 8.4.1. UK
    • 8.4.1.1. Key country dynamics
    • 8.4.1.2. Regulatory framework/ reimbursement structure
    • 8.4.1.3. Competitive scenario
    • 8.4.1.4. UK market estimates and forecasts 2018 to 2030, (USD Million)
  • 8.4.2. Germany
    • 8.4.2.1. Key country dynamics
    • 8.4.2.2. Regulatory framework/ reimbursement structure
    • 8.4.2.3. Competitive scenario
    • 8.4.2.4. Germany market estimates and forecasts 2018 to 2030, (USD Million)
  • 8.4.3. France
    • 8.4.3.1. Key country dynamics
    • 8.4.3.2. Regulatory framework/ reimbursement structure
    • 8.4.3.3. Competitive scenario
    • 8.4.3.4. France market estimates and forecasts 2018 to 2030, (USD Million)
  • 8.4.4. Italy
    • 8.4.4.1. Key country dynamics
    • 8.4.4.2. Regulatory framework/ reimbursement structure
    • 8.4.4.3. Competitive scenario
    • 8.4.4.4. Italy market estimates and forecasts 2018 to 2030, (USD Million)
  • 8.4.5. Spain
    • 8.4.5.1. Key country dynamics
    • 8.4.5.2. Regulatory framework/ reimbursement structure
    • 8.4.5.3. Competitive scenario
    • 8.4.5.4. Spain market estimates and forecasts 2018 to 2030, (USD Million)
  • 8.4.6. Norway
    • 8.4.6.1. Key country dynamics
    • 8.4.6.2. Regulatory framework/ reimbursement structure
    • 8.4.6.3. Competitive scenario
    • 8.4.6.4. Norway market estimates and forecasts 2018 to 2030, (USD Million)
  • 8.4.7. Sweden
    • 8.4.7.1. Key country dynamics
    • 8.4.7.2. Regulatory framework/ reimbursement structure
    • 8.4.7.3. Competitive scenario
    • 8.4.7.4. Sweden market estimates and forecasts 2018 to 2030, (USD Million)
  • 8.4.8. Denmark
    • 8.4.8.1. Key country dynamics
    • 8.4.8.2. Regulatory framework/ reimbursement structure
    • 8.4.8.3. Competitive scenario
    • 8.4.8.4. Denmark market estimates and forecasts 2018 to 2030, (USD Million)
• 8.5. Asia Pacific
  • 8.5.1. Japan
    • 8.5.1.1. Key country dynamics
    • 8.5.1.2. Regulatory framework/ reimbursement structure
    • 8.5.1.3. Competitive scenario
    • 8.5.1.4. Japan market estimates and forecasts 2018 to 2030, (USD Million)
  • 8.5.2. China
    • 8.5.2.1. Key country dynamics
    • 8.5.2.2. Regulatory framework/ reimbursement structure
    • 8.5.2.3. Competitive scenario
    • 8.5.2.4. China market estimates and forecasts 2018 to 2030, (USD Million)
  • 8.5.3. India
    • 8.5.3.1. Key country dynamics
    • 8.5.3.2. Regulatory framework/ reimbursement structure
    • 8.5.3.3. Competitive scenario
    • 8.5.3.4. India market estimates and forecasts 2018 to 2030, (USD Million)
  • 8.5.4. Australia
    • 8.5.4.1. Key country dynamics
    • 8.5.4.2. Regulatory framework/ reimbursement structure
    • 8.5.4.3. Competitive scenario
    • 8.5.4.4. Australia market estimates and forecasts 2018 to 2030, (USD Million)
  • 8.5.5. South Korea
    • 8.5.5.1. Key country dynamics
    • 8.5.5.2. Regulatory framework/ reimbursement structure
    • 8.5.5.3. Competitive scenario
    • 8.5.5.4. South Korea market estimates and forecasts 2018 to 2030, (USD Million)
  • 8.5.6. Thailand
    • 8.5.6.1. Key country dynamics
    • 8.5.6.2. Regulatory framework/ reimbursement structure
    • 8.5.6.3. Competitive scenario
    • 8.5.6.4. Thailand market estimates and forecasts 2018 to 2030, (USD Million)
• 8.6. Latin America
  • 8.6.1. Brazil
    • 8.6.1.1. Key country dynamics
    • 8.6.1.2. Regulatory framework/ reimbursement structure
    • 8.6.1.3. Competitive scenario
    • 8.6.1.4. Brazil market estimates and forecasts 2018 to 2030, (USD Million)
  • 8.6.2. Argentina
    • 8.6.2.1. Key country dynamics
    • 8.6.2.2. Regulatory framework/ reimbursement structure
    • 8.6.2.3. Competitive scenario
    • 8.6.2.4. Argentina market estimates and forecasts 2018 to 2030, (USD Million)
• 8.7. MEA
  • 8.7.1. South Africa
    • 8.7.1.1. Key country dynamics
    • 8.7.1.2. Regulatory framework/ reimbursement structure
    • 8.7.1.3. Competitive scenario
    • 8.7.1.4. South Africa market estimates and forecasts 2018 to 2030, (USD Million)
  • 8.7.2. Saudi Arabia
    • 8.7.2.1. Key country dynamics
    • 8.7.2.2. Regulatory framework/ reimbursement structure
    • 8.7.2.3. Competitive scenario
    • 8.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030, (USD Million)
  • 8.7.3. UAE
    • 8.7.3.1. Key country dynamics
    • 8.7.3.2. Regulatory framework/ reimbursement structure
    • 8.7.3.3. Competitive scenario
    • 8.7.3.4. UAE market estimates and forecasts 2018 to 2030, (USD Million)
  • 8.7.4. Kuwait
    • 8.7.4.1. Key country dynamics
    • 8.7.4.2. Regulatory framework/ reimbursement structure
    • 8.7.4.3. Competitive scenario
    • 8.7.4.4. Kuwait market estimates and forecasts 2018 to 2030, (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Market Participant Categorization
• 9.2. Key Company Profiles
  • 9.2.1. Pfizer Inc.
    • 9.2.1.1. Company overview
    • 9.2.1.2. Financial performance
    • 9.2.1.3. Age benchmarking
    • 9.2.1.4. Strategic initiatives
  • 9.2.2. AbbVie Inc.
    • 9.2.2.1. Company overview
    • 9.2.2.2. Financial performance
    • 9.2.2.3. Age benchmarking
    • 9.2.2.4. Strategic initiatives
  • 9.2.3. Astellas Pharma Inc.
    • 9.2.3.1. Company overview
    • 9.2.3.2. Financial performance
    • 9.2.3.3. Age benchmarking
    • 9.2.3.4. Strategic initiatives
  • 9.2.4. Johnson & Johnson
    • 9.2.4.1. Company overview
    • 9.2.4.2. Financial performance
    • 9.2.4.3. Age benchmarking
    • 9.2.4.4. Strategic initiatives
  • 9.2.5. Viatris Inc.
    • 9.2.5.1. Company overview
    • 9.2.5.2. Financial performance
    • 9.2.5.3. Age benchmarking
    • 9.2.5.4. Strategic initiatives
  • 9.2.6. Teva Pharmaceutical Industries Ltd.
    • 9.2.6.1. Company overview
    • 9.2.6.2. Financial performance
    • 9.2.6.3. Age benchmarking
    • 9.2.6.4. Strategic initiatives
  • 9.2.7. Sanofi S.A.
    • 9.2.7.1. Company overview
    • 9.2.7.2. Financial performance
    • 9.2.7.3. Age benchmarking
    • 9.2.7.4. Strategic initiatives
  • 9.2.8. GlaxoSmithKline plc
    • 9.2.8.1. Company overview
    • 9.2.8.2. Financial performance
    • 9.2.8.3. Age benchmarking
    • 9.2.8.4. Strategic initiatives
  • 9.2.9. Boehringer Ingelheim Pharmaceuticals, Inc.
    • 9.2.9.1. Company overview
    • 9.2.9.2. Financial performance
    • 9.2.9.3. Age benchmarking
    • 9.2.9.4. Strategic initiatives
    • 9.2.9.5. Strategic initiatives
    • 9.2.9.6. Strategic initiatives
  • 9.2.10. Bayer AG
    • 9.2.10.1. Company overview
    • 9.2.10.2. Financial performance
    • 9.2.10.3. Age benchmarking
    • 9.2.10.4. Strategic initiatives
    • 9.2.10.5. Strategic initiatives
  • 9.2.11. Ferring Pharmaceuticals
    • 9.2.11.1. Company overview
    • 9.2.11.2. Financial performance
    • 9.2.11.3. Age benchmarking
    • 9.2.11.4. Strategic initiatives
    • 9.2.11.5. Strategic initiatives